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The dwindling supply of effective treatments for infectious disease is cause for alarm. Searches for anti-
infectives yielding fewer and fewer novel discoveries have been concentrated in overly restricted regions
of target space, screening space, chemical space, and competition space. Appreciating the diverse axes
of these spaces may encourage wider exploration.The Challenge
Biomedical research is under increasing
pressure to put hypotheses to the test of
‘‘translation.’’ For neglected infectious
diseases, interest among academics in
early-stage drug discovery is growing
and opportunities for collaboration with
industry are rising (Table 1). If successful
innovations emerge from these collabora-
tions, they might also advance drug
discovery for infectious diseases that are
not considered neglected, but where the
spread of antibiotic resistance has out-
paced a shrinking supply of new agents
(Figure 1).
The term ‘‘space’’ is often used for an
area of thought or action that presents an
opportunity for exploration. Keeping that
definition in mind, it seems timely to ask,
In what spaces do we operate to discover
smallmoleculeswith antibacterial activity?
What axes describe these spaces? In
what zones within each space have we
been working? At what new coordinates
might it be worthwhile to experiment?
This commentary envisions ‘‘anti-infective
drug discovery space’’ as a larger
sphere of opportunity than traditionally
considered.
Target Space
Most antibiotics in clinical use block
microbial synthesis of nucleic acids,
proteins, cell walls, or folate (Walsh,
2003). Success continues against such
targets (Bax et al., 2010) but with dwin-
dling frequency (Payne et al., 2007). In
retrospect, this is a circumscribed area
of anti-infective target space (shaded
zone in Figure 2), representing one locus
on one axis—a molecular axis that
considers that microbial molecules are
required to cause disease. We can
expand the view of target space by ex-
tending the molecular axis and includingtwo other axes: populational (microbial
heterogeneity) and interactional (the
host-pathogen unit).
An expanded view of the molecular axis
includes much more than the microbe’s
machinery for macromolecular synthesis.
Alsoworthyof blockade are specificmole-
cules whose production may be immate-
rial to the bacterium in vitro but critical
for pathogenesis—namely, virulence
factors (Clatworthy et al., 2007). Points of
attack against virulence factors include
quorum sensing or other mechanisms of
virulence factor induction, delivery of
virulence factors into host cells, and their
molecular actions (Clatworthy et al.,
2007). Blocking the synthesis of small
molecules other than folate is another
credible point of attack. Worthy targets
include the synthesis of high-energyphos-
phate bonds, enzyme cofactors, key
metabolites, and antioxidants. Targets
need not be limited to biosynthetic
pathways at all but can include other key
aspects in the life cycle of a macromole-
cule, such as its processing, posttransla-
tional modification, detoxification, repair,
and degradation. Such processes are
often involved in resisting host immunity
(Lin et al., 2009). Additional life processes
distinct from synthesis are signaling path-
ways that permit adaptation to conditions
in the host and the maintenance of gradi-
ents of protons and metals.
A second axis that can define target
space draws attention to bacterial
subpopulations, particularly those that
are actively replicating and those that
are more quiescent (Lewis, 2010). While
the essentiality of some gene products
is replication independent, others are
required for bacterial survival only in repli-
cating or only in nonreplicating bacteria.
Conditional essentiality may also apply
to genes expressed in bacteria residingCell Host & Microbin microenvironments that differentially
affect the pathogen’s metabolic state,
such as intracellular or extracellular
residence; aerobic, hypoxic, or anoxic
conditions; or planktonic or biofilm
communities.
A third axis draws attention to host-
pathogen interactions. Almost all anti-
infectives have been selected for their
ability to stop the growth of or kill the
pathogen as it is cultured in vitro.
The host has been regarded as a large,
complex, multicompartmental culture
vessel in which to achieve a high-enough
level of a safe-enough compound to
replicate the results obtained in vitro.
This ignores the anti-infectious contribu-
tions of the host, beyond assuming that
they contribute to cure. In fact, the host
environment may antagonize the action
of anti-infectives. A common outcome of
a host response that has not been suffi-
cient to eliminate the pathogen is to drive
some members of the pathogenic micro-
bial population into a nonreplicative state.
This maymake themphenotypically resis-
tant to anti-infectives that were selected
for their ability to prevent bacterial replica-
tion by blocking an increase in biomass.
Some pathogens exploit host-encoded
factors that the host can temporarily do
without. In such cases, molecular targets
of anti-infectives could be host encoded.
Anti-infectives that inhibit targets in the
host might serve as adjunctive therapeu-
tics whose special value might lie in the
rarity of microbial resistance against them.
Screening Space
Drugs can be designed to fit an active site
or mimic a cofactor or intermediate.
However, screening large numbers of
compounds is likely to remain the
major corridor through which most new
anti-infectives enter development. Thee 9, May 19, 2011 ª2011 Elsevier Inc. 343
Table 1. Recent Examples of Innovative Partnerships between Pharmaceutical Companies and Academics for Drug Discovery for
Neglected Infectious Diseases and Other Therapeutic Indications*
Year Company Key Features
2005 Novartis Institute for Tropical Disease Research Bill and Melinda Gates Foundation Grand Challenges grant
supported in-house screening of TB drug targets nominated
by the academic partners.
2007 Lilly TB Drug Discovery Initiative Eli Lilly, Inc. established a partnership with NIH, Academia Sinica,
and the not-for-profit Infectious Disease Research Institute (IDRI)
in which a broadly based steering committee reviews applications
from academics and biotech firms for TB drug discovery, leading
to screening of Lilly compounds at IDRI and other assistance.
2010 GlaxoSmithKline The firm established the ‘‘Open Laboratory’’ at Tres Cantos, Spain
for up to 60 academic and biotech scientists to screen the
corporate compound collection, set up a foundation that can
support visitors’ expenses, and placed 700 relevant patents in
a public pool.
2010 Novartis Institute for Tropical Disease Research
and Genomics Institute of the Novartis Research Foundation
With support from Wellcome Trust, Novartis collaborated with
academic labs to screen the corporate compound collection in
search of antimalarials.
2011 Pfizer The firm is opening regional Centers for Therapeutic Innovation
at which academic and company scientists will work together
on jointly chosen projects.
2011 AstraZeneca and Sanofi-Aventis The More Medicines for Tuberculosis (MM4TB) consortium
funded by the European Union includes several universities
coordinated by S. Cole of Ecole Polytechnique Federale de
Lausanne.
* Examples are exclusive of activities managed by public-private partnerships that contract with pharmaceutical firms, such as Medicines for Malaria
Venture, Global Alliance for TB Drug Discovery, and Drugs for Neglected Diseases Initiative. These collaborative models have emerged against
a backdrop of calls from within the industry for new organizational models for research and development (Cuatrecasas, P. [2006]. Drug discovery
in jeopardy. J. Clin. Invest. 116, 2837–2842; Garnier, J.P. [2008]. Rebuilding the R&D engine in big pharma. Harv. Bus. Rev. 86, 68–70, 72–66, 128;
Munos, B. [2009]. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959–968; Paul, S.M., Mytelka, D.S., Dunwiddie,
C.T., Persinger, C.C., Munos, B.H., Lindborg, S.R., and Schacht, A.L. [2010]. How to improve R&D productivity: the pharmaceutical industry’s
grand challenge. Nat. Rev. Drug Discov. 9, 203–214). Thus, there is growing pressure to experiment with new routes to innovation and new ways
to collaborate that reduce risk and redundancy and expand opportunity.
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terize a screen is the number of com-
pounds tested. No matter how large this
number, screening space is a confining
passageway, particularly when it is unidi-
mensional. Instead consider three axes:
the size and state of the pathogenic unit
screened, the number of compounds
and targets in an individual test, and
the way the information obtained is put
to use.
The first axis calls attention to the size
and nature of the unit against which
compound collections are screened. At
one extreme, the unit can be submolecu-
lar: an active site, allosteric site, or site of
interaction with a partner in a complex.
Submolecular sites are often screened
with a few hundred small-molecule ‘‘frag-
ments’’ whose binding is analyzed by
NMR or X-ray crystallography. A focused
synthetic effort links together fragments
that bind neighboring subsites (Hajduk
et al., 2011).344 Cell Host & Microbe 9, May 19, 2011 ª20Zooming out from the submolecular
level, commonly the target is a purified
enzyme whose essentiality for pathogen-
esis has been confirmed by genetic
manipulation. The advantage of target-
based screens is the frequency with
which potent inhibitors can be identified,
the opportunity to improve them by
structure-guided methods, the ability to
monitor pharmacodynamics, and an
enhanced ability to analyze mechanisms
of resistance. However, it is rarely
possible to predict which compounds
will enter the pathogen (O’Shea and
Moser, 2008), be retained in an active
form at effective concentrations, and
inhibit the target in the intrabacterial
milieu, where concentrations of
substrates, ions, and regulatory factors
may differ markedly from those in the
screening assay. Multimolecular targets
may be complexes of proteins and nucleic
acids, such as the ribosome, transcrip-
tional preinitiation complex, or spliceo-11 Elsevier Inc.some, or complexes of lipids and
proteins, such as the bacterial membrane.
Going one step up from there are
whole-cell screens, which use the intact
pathogen. This avoids the disadvantages
of target-based screens but forfeits the
advantages, at least temporarily. An
effective inhibitor is sorely handicapped
for drug development until its target is
identified. The search for the target can
be demanding and even fruitless. Many
clinically effective anti-infectives have
multiple targets (Silver, 2007). That can
make target identification problematic by
precluding the isolation of mutants
that are resistant by virtue of a mutation
in the target. Traditionally, whole-cell
screens have employed conditions
that allow the pathogen to grow at the
fastest rate that can readily be sup-
ported. However, these conditions rarely
resemble host niches, which often
provide pathogens with far less oxygen,
iron, and nutrients than the conditions
Figure 1. Main Building at Uppsala Universitet in Sweden, Site of the
Conference ‘‘The Global Need for Effective Antibiotics—Moving
Towards Concerted Action’’ (September 6–8, 2010)
Princess Victoria joined ministers of national governments, European Union
officials, industry executives, foundation officers, economists, legal scholars,
clinicians and scientists to consider the threat that society faces from the dwin-
dling supply of effective antibiotics. The meeting was organized by ReAct–
Action on Antibiotic Resistance (http://www.reactgroup.org) to address
amounting concern that the practice of modern medicine may become unsus-
tainable unless we reverse a perfect storm: a steep decline in antibiotic
discovery combined with spreading resistance to existing agents (Nathan,
C. [2004]. Antibiotics at the crossroads. Nature 431, 899–902). A summary
of the conference proceedings is available (So, A., N. Gupta, S. Brahmachari,
I. Chopra, B. Munos, C. Nathan, K. Outterson, J.P. Paccaud, D. Payne, R.
Peeling, M. Spigelman, J. Weigelt [2011]. Towards New Business Models for
R&D for Novel Antibiotics. Drug Resistance Updates, in press).
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screening assay. Thus, a crit-
ical issue in whole-cell
screening is the metabolic
state of the cells.
A unit of screening with
even greater complexity and
potential reward is an infected
host cell in vitro. Such screens
can identify compounds that
enter the same host-cell
compartment as the path-
ogen without killing the host
cell. Besides the inapplica-
bility of this method to extra-
cellular pathogens, disadvan-
tages include that the host cell
is usually a transformed cell
line that bears limited resem-
blance to primary cells, has
been removed from the influ-
ence of the immune system,
and is typically cultured
under conditions that differ
markedly from those in vivo.
The largest and most
complex unit screened is an
experimentally infected host.
The most rewarding hosts
are those in which the patho-
physiology, including the
immune response, resembles
that of humans. Pyrazina-
mide, one of the few steril-
izing drugs available to treat
tuberculosis, is inactive under
standard screening condi-
tions in vitro and was only
discovered to be active
because it was first tested in
mice. This is a powerful
reminder that the most valu-
able region along the unit
axis of screening space is
the one least used. Workingat this point on the axis is considered
prohibitively expensive. However, if the
costs of failure elsewhere along the axis
were factored in and a smaller number
of more appropriate compounds tested,
the cost-benefit ratio might not seem
adverse.
A second axis of screening space calls
attention to the population size of
compounds or targets being screened in
each assay. Often there is one compound
per well and its interaction with one
target is studied. However, orthogonally
compressed libraries can offer a markedincrease in efficiency. For example, ten
compounds can be present in each well
with nine different partners in a second
well. From the pattern of active wells one
can deduce which compound is likely to
be active and then test it in isolation.
Even larger numbers of compounds can
be tested in a single well if they are individ-
ually tagged and can be isolated on the
basis of binding the target.
Combination chemotherapy entered
medical practice when it was found to
improve efficacy and delay the emergence
of drug resistance in tuberculosis. FromCell Host & Microbe 9, May 19,there, it was adopted for
cancer chemotherapy, found
its way back to the chemo-
therapy of bacterial infections
with b-lactams/b-lactamase
inhibitors and trimethoprim/
sulfamethaxazole, and proved
its worth yet again in HIV/AIDS
and malaria. Despite the
impressive track record of
combination chemotherapy,
we lack an organized way
to develop it. We assemble
combinations empirically from
agents that were developed
to act singly. We rarely exploit
synthetic lethality, which
would guide us to compounds
that kill the pathogen particu-
larly well when used together.
To seek synergistically inter-
acting compounds by intent
would open up a vast new
area of screening space. For
example, one can incubate
the pathogen (under host-
relevant conditions) with a
sublethal concentration of an
approved drug, a drug candi-
date, or a lead compound
and then screen a library for
compounds that enhance the
first agent’s activity. Alterna-
tively, predictive maps of
synthetic lethality can call
attention to potential target
pairs (Nichols et al., 2011) for
which inhibitors can be identi-
fied separately.
A third axis of screening
space calls attention to how
we use the enormous quanti-
ties of information generated.
Unfortunately, most of the
information obtained fromscreening is currently wasted. Com-
pounds that meet some predetermined
cutoff are typically only <0.1% of those
tested. Among the actives, those that
prove toxic to mammalian cells are
typically discarded. All the screening
information can potentially be mined.
Structurally similar compounds that
gave negative results can help provide
a preliminary structure-activity relation-
ship. For example, rather than treating
inhibition as a binary property (yes/no),
it can be treated as a continuous variable
and used to rank compounds, infer2011 ª2011 Elsevier Inc. 345
Figure 2. Target Space
Conventional anti-infective drug discovery has largely been confined to the
blue-shaded area. Similar diagrams could be constructed for screening space,
chemical space, and competition space, as described in the text.
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and predict new actives in
an iterative process that can
increase screening efficiency
dramatically (Duffy, 2010).
Another potential use of
otherwisewasted information
is to tackle the challenge of
predicting whether a partic-
ular compound can enter
into a given bacterial species.
Compounds that kill bacteria
in whole-cell screens have
almost always entered them.
Even if the compound’s inhib-
itory activity is less than the
threshold set for exploring its
potential to lead to an anti-
bacterial agent or even if the
compound is cytotoxic, it
serves to report probable
microbial penetration. The
structures of all compounds
that inhibit a given pathogenin a whole-cell screen could be used to
refine cheminformatic approaches for
predicting uptake into bacteria. This could
be achieved collaboratively and confiden-
tially to the mutual benefit of companies
that otherwise compete.
Chemical Space
Sulfonamides, the first antibacterial drugs
of known structure, were based on
a synthetic dye. However, their mecha-
nism of action depends on their fortuitous
resemblance to a natural product,
p-aminobenzoic acid. Penicillin, which
introduced the next structurally defined
class of anti-infectives, was the product
of a fungus. Today,most classes of antibi-
otics, even if fully synthetic, are based on
natural products. Nonetheless, the far
greater ease of combinatorial chemical
synthesis than natural product synthesis
led many pharmaceutical firms to close
out their natural product collections and
screen for anti-infectives using the same
compounds as used for other therapeutic
areas. Unfortunately, such compounds
rarely enter bacterial pathogens (O’Shea
and Moser, 2008). Another criterion used
to select compounds for screening has
been the retrospective analysis of proper-
ties of orally active drugs (Lipinski and
Hopkins, 2004; O’Shea and Moser,
2008). For example, orally active drugs
generally have a molecular mass below
500 daltons, no more than five hydrogen346 Cell Host & Microbe 9, May 19, 2011 ª20bond donors and ten hydrogen bond
acceptors, and lipophilicity limited
enough to give a ratio of less than 105
for the compound’s distribution between
octanol and water. Regrettably, anti-
infectives often fail to conform to the
generalizations derived from such anal-
yses (Lipinski and Hopkins, 2004;
O’Shea and Moser, 2008).
By one estimate there could be >1060
compounds containing %30 atoms of
carbon, nitrogen, oxygen, and sulfur
(Bohacek et al., 1996). This doesn’t
take into account fluorine and boron,
atoms that are increasingly popular in
drug discovery. Thus, no matter how
prodigiously we screen small molecules,
we will never sample more than a minute
area of chemical space (Lipinski and
Hopkins, 2004). It follows that the
criteria by which compounds are selected
for screening will predetermine the
results. Yet the criteria most often
used involve what are meant to be
pragmatic factors, such as cost, avail-
ability, and low reactivity. The result is
an extensive overlap in the compounds
represented among independently
assembled collections. This redundancy
means that the proportion of chemical
space sampled is vastly smaller than
implied by the number of screens con-
ducted and the number of compounds
screened in each. Further, the apparent
pragmatism of the criteria used for selec-11 Elsevier Inc.tion is challenged by the low
rate of success that ensues.
To characterize chemical
space in a way that encour-
ages greater exploration we
can imagine axes relating to
molecular diversity, presyn-
thetic selection, and postsyn-
thetic selection.
On thefirstaxis, theextentof
molecular diversity is defined
by traditional cheminformatic
criteria: compositional dissimi-
larity, shape, polar surface
area, number of rotatable
bonds, extent and distribution
of hydrophobicity, hydrophi-
licity, charge, electrophilicity
and nucleophilicity, number
of hydrogen bond donors
and acceptors, intrinsic reac-
tivity, andpresenceof optically
active centers.
However, a second axiscould direct attention to whether selec-
tive forces were applied before the
compound’s synthesis. If the compound
is a product of a bacterium, fungus, coral,
or plant, it is likely that its chemical prop-
erties were subject to natural selection to
optimize a function. It may be a secondary
metabolite, a small molecule with
a specialized role often related to intra-
or interspecies signaling. Farther along
this axis lie ‘‘naturaloid’’ compounds.
These include compounds produced by
recombinant organisms using enzymes
encoded by genes in nonnative combina-
tions and contexts. Other ‘‘naturaloid’’
products are designed by humans to
mimic natural products in their complexity
and chirality while allowing synthesis of
analogs (‘‘hit expansion’’) with greater
facility, as in diversity-oriented synthesis
(Hajduk et al., 2011). At the opposite
pole are compounds whose synthesis
was guided and bounded by other human
concerns and capabilities.
A third axis could reflect the degree
to which compounds are preselected
according to presumptions of desirable
properties. As was noted above,
compounds that are not considered
‘‘drug-like’’ are often excluded, but
the criteria are not based on their efficacy
as anti-infectives. Equally important,
compounds considered likely to be
reactive are often excluded, although the
efficacy of many drugs depends on their
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including penicillin, arguably the most
important anti-infective in history. More-
over, reactivity is beneficial when
a compound resembles a substrate
closely enough to be acted on by
a microbial enzyme and incorporated
into a product that inhibits the same
and/or other enzymes (Robertson, 2005).
Competition Space
Any endeavor to discover new anti-infec-
tives in a resource-constrained setting
competes with other undertakings.
Competition affects drug discovery at
every step, from project selection to
product utilization. It is important to
consider how priorities are set, because
it may be better for industry and society
to position some projects at diverse coor-
dinates in ‘‘competition space.’’
Purpose, process, and payout are axes
of competition space. Purpose can range
from maximizing financial return on
investment to addressing medical need.
Process can range from committee
consensus (as at NIH and in industry) to
an individual innovator’s recognition of
innovation (as used by the Bill and Me-
linda Gates Foundation to select some
projects). Payout refers to the source of
monetary reward for a product. It has
a profound impact on project prioritization
whether the reward for drug discovery will
derive from sales at monopoly-protected
prices or from a multinational fund based
on reduction in the burden of disease
(Banerjee et al., 2010).
Space Exploration: Why Now?
Is industrial attention to infectious
diseases likely to grow and be sustained?
The answer depends onwhether the lead-
ership can afford to take a strategic view
and whether that view identifies an
economic advantage. In fact, if scientific
and regulatory obstacles can be over-
come, there are compelling economic
reasons for pharmaceutical companies
to invest in making new anti-infectives,
over and above the attraction that compe-
tition eased whenmany firms left the field.
Emerging markets are a major driver.
Sales in developed-country markets are
constrained by price regulation and
competition from generics while revenue
potential is rising in middle-income coun-
tries. More economies will become
middle income when infectious diseasesclaim fewer lives. Multinational compa-
nies are hiring and placing more staff in
regions afflicted by infectious diseases
and must protect their human resources.
Given that a large share of pharmaceutical
profits comes from the long-term treat-
ment of chronic diseases like atheroscle-
rosis, obesity, diabetes, asthma, osteo-
porosis, cancer, neurologic disease, and
mental illness, raising life expectancy by
curbing infectious disease mortality aids
market growth. Multinational pharmaceu-
tical companies must compete with in-
country firms for standing with regulators
and customers and can do so by
providing cures for life-threatening infec-
tions. Rapidly curative therapies help
balance portfolios that are stocked with
prolonged, palliative treatments that
demand an ultra-low-risk-benefit ratio
and impose a high cost for late-emerging,
low-incidence toxicities.
Market abuses, biased information
control, and manufacturing lapses have
tarnished the industry’s image. Devel-
oping cures for life-threatening infections
at a time of rising public concern over
dwindling therapeutic options can restore
public confidence and employee morale.
Conversely, it would incur enormous ire
to allow the attrition of anti-infectives to
continue to the point that surgical
mortality surges, premature babies die
routinely, pneumonia often kills, and
bone-marrow transplantation is aban-
doned, all because of increasingly incur-
able bacterial infections.
Conclusions
When anti-infective drug discovery began
to run out of steam, it was largely confined
to the following niches in target,
screening, chemical, and competition
space: screens focused on four major
biosynthetic pathways inmicrobes essen-
tial for building biomass, and within that,
a subset of targets shared by numerous
pathogens. Whole microbial cell screens
were conducted such that the microbes
lacked for nothing andgrewat their fastest
rate, ignoring conditions in the host.
Targets were selected one at a time
with no advance provision for using anti-
infectives in combination. Compound
collections were screened that were avail-
able for purchase or convenient to make
by parallel synthesis and that were
enriched with analogs of drugs that inhibit
human targets and were good at enteringCell Host & Microbhumans but not microbes. Over 99.9% of
the information gained in each screen
was discarded. Campaigns to discover
anti-infectives were launched only if they
could forecast a return on investment
comparable to what could be expected
from selling a product under monopoly
prices to very large numbers of affluent or
well-insured people with chronic diseases
who, being helped but not cured, would
use it indefinitely. It is no surprise that
anti-infective drug discovery nearly came
to a halt. Given that a prolonged halt will
prove catastrophic, every aspect of this
depiction needs to be rethought.
The space metaphor used here is to
help free us from confined thinking,
and we must not allow it to introduce
constraints of its own. Only for purposes
of discussion did we imagine a given
space as having three dimensions.
Target, screening, chemical and compe-
tition space can each be considered one
of the dimensions of anti-infective
discovery space. What other dimensions
might help us find our way out of the tight
spot in which we find ourselves?
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